{"entity":{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","aka":[],"tldr":"Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer.","summary":"Christopher Sweeney (University of Adelaide; formerly Dana-Farber) was principal investigator of CHAARTED, the ECOG trial showing early docetaxel with androgen deprivation adds more than a year of survival in high-volume metastatic hormone-sensitive prostate cancer, and co-led ENZAMET (enzalutamide) with ANZUP. His work established treatment intensification at diagnosis as the standard approach. He now directs an immunogenomics institute in South Australia.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweeney%20CJ%5BAuthor%5D%20prostate%20docetaxel"}],"tags":["prostate","trialist","ecog-acrin"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["androgen-deprivation","cytotoxic-chemotherapy"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":["saigenci-adelaide"],"pathways":[],"terms":[],"trials":["chaarted"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, South Australian Immunogenomics Cancer Institute; Professor, University of Adelaide","institutionId":"saigenci-adelaide","specialisms":["Metastatic hormone-sensitive prostate cancer","Docetaxel and androgen receptor inhibitors","Cooperative-group trials","Immunogenomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweeney%20CJ%5BAuthor%5D%20prostate%20docetaxel"}],"papers":[{"title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer (CHAARTED)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1503747"},{"title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer (ENZAMET)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903835"}],"orcid":"0000-0002-0398-6018"},"route":"/people/christopher-sweeney/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"institution":[{"id":"saigenci-adelaide","kind":"institution","name":"South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide","route":"/institutions/saigenci-adelaide/"}],"trial":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/"}],"paper":[{"id":"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","kind":"paper","name":"STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis","route":"/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/"}]}}